BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16687949)

  • 1. Angiotensin receptor blockers: new considerations in their mechanism of action.
    Sica DA
    J Clin Hypertens (Greenwich); 2006 May; 8(5):381-5. PubMed ID: 16687949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
    Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
    Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
    Dendorfer A; Dominiak P; Tempel K; Raasch W
    J Hypertens; 2005 Oct; 23(10):1861-7. PubMed ID: 16148610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
    Leenen FH; Yuan B
    Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 receptor blockers.
    Burnier M
    Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
    [No Abstract]   [Full Text] [Related]  

  • 9. Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
    Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):181-7. PubMed ID: 12563569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor blockers. A new class of antihypertensive drugs.
    Velasquez MT
    Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
    Nap A; Balt JC; Pfaffendorf M; Van Zwieten PA
    J Hypertens; 2002 Sep; 20(9):1821-8. PubMed ID: 12195125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Kusunoki H; Taniyama Y; Rakugi H; Morishita R
    J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
    Shetty SS; DelGrande D
    J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan: review of pharmacology and comparative properties.
    Adams MA; Trudeau L
    Can J Clin Pharmacol; 2000; 7(1):22-31. PubMed ID: 10822210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Grossman E; Messerli FH; Neutel JM
    Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
    Belz GG; Butzer R; Kober S; Mutschler E
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.